Charles River latest CRO to muscle in on Phase I

By Kirsty Barnes

- Last updated on GMT

Related tags: Phase, Clinical trial, Contract research organization, Pharmacology, Us

Charles River Laboratories is the latest in a series of large
contract research organisations making acquisitions to beef up
their Phase I capacity as this market sector remains hot.

The US firm has bought privately-held Northwest Kinetics of Tacoma, Washington for $29.5m (€23m), giving the company its first Phase I facility in the US. Northwest, which specialises in branded-drug studies, currently has a 150-bed facility which will be expanded to 250 beds by the end of the year - bringing Charles River's total Phase I capacity to 300 beds in combination with its existing Phase I facility in Scotland. In May this year, Charles River made a strategic decision to purge itself of its flagging Phase II-IV Clinical Services unit, which it sold to Kendle, to focus instead on its core drug discovery and development services, including its small Phase I business which it is now trying to build up. Early phase clinical trial services are a strong growth area in the US and globally as they continue to be one of the biggest bottlenecks in the development of new drugs and as a result the sector is experiencing a flurry of activity. Only a few weeks ago Parexel acquired California Clinical Trials Medical Group (CCT) and Behavioral and Medical Research (BMR) - a $65m US business that will inflate its early phase capacity to over 400 beds, making it one of the largest providers of Phase I services in the world. Parexel's larger rival Covance has also been beefing up its Phase I capacity this year, buying eight early-phase clinical development sites in the US from Radiant Research in May. Like Parexel, these acquisitions also gave Covance a significant expansion of clinical pharmacology bed capacity, bringing the firm's global Phase I/IIa clinical research capacity to more than 500 beds across eleven sites, and broadening its access to special patient populations for Phase Ib/IIa clinical studies. In addition there have also been a number of small start up CROs in the field this year.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars